LGND

#1373
Ligand Pharmaceuticals Inc.
226.1800 USD
-2.65%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
225.7500
230.4300
年范围
175.8900
234.7600
日变化
-2.65%
每月变动
+10.71%
6个月变化
+20.87%
年变化
+20.87%
前一天收盘价
232.3400
开盘价
230.4300
买价
卖价
最低价
225.7500
High
230.4300
交易量
29
展开完整图表

Financials

概览 声明 统计 股息
每季度 年度
  • Market Capitalization 4.5103 B
  • Employee 47
  • Founded N/A
  • CEO N/A
  • Website www.ligand.com
  • Headquarter Delaware, United States
  • FIGI BBG000BKF014
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
30.84
市销率
14.31
每股股息
2.5
股息收益率 %
1.32

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020.

新闻